These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35333446)

  • 1. Benefits of weight loss of 10% or more in patients with overweight or obesity: A review.
    Tahrani AA; Morton J
    Obesity (Silver Spring); 2022 Apr; 30(4):802-840. PubMed ID: 35333446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity Management in Adults: A Review.
    Elmaleh-Sachs A; Schwartz JL; Bramante CT; Nicklas JM; Gudzune KA; Jay M
    JAMA; 2023 Nov; 330(20):2000-2015. PubMed ID: 38015216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
    Garvey WT
    Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
    Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
    JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination phentermine and topiramate extended release in the management of obesity.
    Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity: Pharmacotherapy.
    Powell A
    FP Essent; 2020 May; 492():25-29. PubMed ID: 32383845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
    Grunvald E; Shah R; Hernaez R; Chandar AK; Pickett-Blakely O; Teigen LM; Harindhanavudhi T; Sultan S; Singh S; Davitkov P;
    Gastroenterology; 2022 Nov; 163(5):1198-1225. PubMed ID: 36273831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options.
    Cannon CP; Kumar A
    Clin Cornerstone; 2009; 9(4):55-68; discussion 69-71. PubMed ID: 19789064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US.
    Czepiel KS; Perez NP; Campoverde Reyes KJ; Sabharwal S; Stanford FC
    Front Endocrinol (Lausanne); 2020; 11():290. PubMed ID: 32477270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review.
    Horn DB; Almandoz JP; Look M
    Postgrad Med; 2022 May; 134(4):359-375. PubMed ID: 35315311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review).
    Henry RR; Chilton R; Garvey WT
    J Diabetes Complications; 2013; 27(5):508-18. PubMed ID: 23726071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination phentermine/topiramate for obesity treatment in primary care: a review.
    Xiong GL; Gadde KM
    Postgrad Med; 2014 Mar; 126(2):110-6. PubMed ID: 24685974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Shi Q; Wang Y; Hao Q; Vandvik PO; Guyatt G; Li J; Chen Z; Xu S; Shen Y; Ge L; Sun F; Li L; Yu J; Nong K; Zou X; Zhu S; Wang C; Zhang S; Qiao Z; Jian Z; Li Y; Zhang X; Chen K; Qu F; Wu Y; He Y; Tian H; Li S
    Lancet; 2024 Apr; 403(10434):e21-e31. PubMed ID: 38582569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaglutide for the treatment of overweight and obesity: A review.
    Bergmann NC; Davies MJ; Lingvay I; Knop FK
    Diabetes Obes Metab; 2023 Jan; 25(1):18-35. PubMed ID: 36254579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.
    Iannone A; Natale P; Palmer SC; Nicolucci A; Rendina M; Giorgino F; Laviola L; Di Leo A; Strippoli GFM
    Diabetes Obes Metab; 2023 Sep; 25(9):2535-2544. PubMed ID: 37254688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
    Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
    J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.